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Edited by Robert Russell and Giulio Superti-FurgaAbstract An important challenge facing researchers in drug
development is how to translate multi-omic measurements into
biological insights that will help advance drugs through the clinic.
Computational biology strategies are a promising approach for
systematically capturing the eﬀect of a given drug on complex
molecular networks and on human physiology. This article
discusses a two-pronged strategy for inferring biological interac-
tions from large-scale multi-omic measurements and accounting
for known biology via mechanistic dynamical simulations of
pathways, cells, and organ- and tissue level models. These ap-
proaches are already playing a role in driving drug development
by providing a rational and systematic computational frame-
work.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Much of the success of Gleevec can be attributed to the re-
search investment made in elucidating the biology underlying
chronic myelogenous leukemia (CML) and understanding
the role of inhibiting the activity of its intended target p210
BCR-ABL kinase [1]. However, several of the current drugs
in development have been advanced with a sparse knowledge
of the biological factors that contribute to the lack of eﬃcacy
and/or safety (especially for oncology). There is a growing con-
sensus in the pharmaceutical industry that a more systematic
approach to drug development is needed to translate genomic
discoveries into successful drugs [2]. Biological insights into
disease pathogenesis and progression, as well as an under-
standing of drug epidemiology would drive a more rational ap-
proach to drug development. Under this fundamental concept,
three main approaches emerge that will be valuable in reducing
attrition rates and advancing drugs through the clinic: (1) pre-*Corresponding authors.
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doi:10.1016/j.febslet.2005.02.012dicting and understanding biological interactions and causal
eﬀects of the drug on disease progression/prevention, (2) pre-
dicting and understanding the mechanisms of action for
drug-induced toxicity, and (3) identifying the corresponding
biomarkers, key molecular endpoints that must be monitored
to ensure success of clinical trials or eliminate possible failures
early during clinical development [3]. All three approaches also
need to be conducted in conjunction with an adequate descrip-
tion of drug pharmacokinetics.
Signiﬁcant eﬀort to determine these biological endpoints
centers around multi-omic proﬁling, namely genomic, proteo-
mic and metabolomic information which are often coupled
with appropriate phenotypic, physiological, pharmacogenetic,
and/or clinical measurements (e.g., tumor volume in oncol-
ogy). Using various statistical methods for analyzing these
data, researchers are able to discover genes involved in disease
pathogenesis and progression, determine drug eﬃcacy and tox-
icity, and identify biomarkers that correlate with drug response
[4]. For example, Dracopoli describes a preclinical oncology
study where six potential biomarkers were identiﬁed via
mRNA proﬁling. The study compared the most highly ex-
pressed genes to those that were downregulated after treatment
with a drug [5]. These markers could be used to identify pa-
tients most likely to respond to a drug in a clinical trial follow-
ing prior validation via genomic measurements from patient
biopsies.
Thus, high-throughput multi-omic data coupled with statisti-
cal analysis represent an important ﬁrst step towards gaining
biological insights into how drugs work and determining clini-
cally predictive molecular endpoints. However, being able to
identify potential molecular constituents does not necessarily
translate into biological insights on disease and drug mecha-
nisms. One of the challenges is to establish the predictability
of the biomarkers as relevant endpoints in human in the clinical
setting. Most diseases are far too complex to be determined by
the activity of one rogue kinase as is the case with CML. Even
in the case of this well-understood disease, complexity may also
arise due to adaptive system responses, namely resistance with
disease progression. Experimental characterization of selected
markers can provide additional insights, but this is necessarily
a local analysis of a few molecular endpoints that may not be
representative of the underlying complex biological system.
Ultimately, computational approaches are needed to captureblished by Elsevier B.V. All rights reserved.
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networks and on human physiology.
Progress in drug development eﬀorts requires a two-pronged,
yet intertwined computational biology strategy that can: (1) in-
fer new (and conﬁrm existing) biological relations using ap-
proaches based on reverse-engineering, learning algorithms,
and data-mining techniques applied to large-scale high-
throughput data; and (2) account for known biology via
mechanistic dynamical simulations of pathways, cells, and
organ- and tissue-level models (Fig. 1). In the ﬁrst approach,
multi-omics data can be incorporated into a framework that in-
fers molecular interactions on a global scale and causally links
such interactions with phenotypic, physiological, and/or clini-
cal endpoints. Hence, the inferred connections represent inte-
grated aspects of the disease pathology and, importantly,
reﬂect how the drug of interest may aﬀect the network. In a sub-
sequent step, key interactions predicted from this framework
can be used to inform the mechanistic simulations of the path-
ways underlying the disease state and drug interaction. These
models explore dynamics of molecular interaction and may in-
clude multiple scales and diﬀerent levels of resolution depend-
ing on the disease being modeled, the available data, and the
detailed questions to be addressed by the modeling eﬀort.
In this review, we broadly describe the components of this
two-pronged computational biology approach and the impact
it may have on driving drug development. We also provide
case studies and examples that demonstrate utility of these
approaches.Fig. 1. Combined inference and mechanistic modeling framework.
High-throughput multi-omic measurements on drug response can be
incorporated into an inference modeling framework that predicts
molecular interactions on a global scale. Results from this can inform
the mechanistic simulations of the pathways underlying the disease
state and the drug interaction. Detailed mechanistic models require
dynamical time course measurements on multiple levels (e.g., phos-
phoproteins, proteins, RNA). The combined approach yields more
accurate models of drug biological response.2. Inference modeling for drug development
The challenge for researchers using multi-omic approaches
to determine eﬃcacy, toxicity, and corresponding biomarkers
is to go beyond observing constituent parts (genes, proteins,
and metabolites) to a systems or networks level of understand-
ing, emphasizing causal connections. Much of the data-mining
eﬀorts have focused on ﬁnding patterns (signatures) and corre-
lations within the large-scale multi-omic datasets [6]. However,
processing the extracted information can be challenging. Nec-
essarily, data-mining approaches need to go beyond pure pat-
tern recognition, correlations, and comparisons to known
pathway maps in order to maximize the information content.
For example, computational tools such as Cytoscape [7,8] al-
low for the mapping and possibly integration of static biomo-
lecular interaction networks with high-throughput expression
data.
New algorithmic approaches for reconstruction of the
underlying structure of large-scale multi-omic data have re-
cently emerged. One class of approaches relies on deterministic
reverseengineering techniques [9,10], while other approaches
use a range of probabilistic learning methods [11–17]. Among
these, inference algorithms based on Bayesian Networks (BN)
have shown promising potential to partially reconstruct bio-
logical networks [18–22]. For example, BN algorithms have
been used to infer probabilistic graph models of gene regula-
tory networks from genomic expression data [21,22]. The
advantages of such methods include the ability to integrate
heterogeneous datasets across multiple levels of biological
organization [22]. They can also be applied on a portion of
the overall network for further detailed inference work, and
may be optimized via the use of prior biological knowledge.
Technically, they may capture linear, non-linear, combinato-
rial, stochastic, and other types of relationships among vari-
ables. Also, BN algorithms may be optimized to handle
noisy data as typically found in biological experiments.
2.1. Inference modeling platform
Scientists at Gene Network Sciences (GNS) have developed
an inference computational framework based on BN algo-
rithms. The framework utilizes multi-omic data, along with
corresponding phenotypic, physiological, and/or clinical end-
point data, to construct regulatory models 1 underlying the
patho-physiology of interest and the corresponding drug ef-
fects. The inference engine can also utilize knowledge on pos-
sible cellular interactions and other biological causal
relationships from the literature (via manual curation or
text-mining tools) or bioinformatics methods that determine
gene–gene and protein–protein interactions [23–25] to precon-
dition the search space over all possible network topologies
that ﬁt the data. Such preconditioning or ‘‘prior knowledge’’
helps to achieve convergence in the search space and does
not aﬀect the ﬁnal recovered networks, which is completely
determined by the constraining data. The inference engine pro-
duces an ensemble of inferred graph models. Within this net-
work ensemble, probabilities are assigned to the inferred
connections (‘‘edges’’) between network nodes (which repre-
sent molecular entities or higher-level readouts) that allow a1 Regulatory models in this article refers to the molecular networks
(genes, proteins, and metabolites) underlying cellular and physiological
response.
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interrogate and investigate portions of the overall network
ensemble.
Additionally, kinetic data (time course measurements) can
be used in an inference modeling framework to recover, at least
partially, a causality-of-events among the inferred connections.
Such causality is essential to reveal the chain of events that led
to the observed drug eﬀects in the context of biologically plau-
sible pathways. An inference framework of this sort allows for
marker identiﬁcation and qualiﬁcation given a set of proﬁling
data and prior literature knowledge. Key to utilizing such a
method is to obtain a set of measurements for the model enti-
ties (network nodes) of interest under a suﬃcient number of
diﬀerent conditions that perturb the biological system. Such
perturbation experiments include, for example, diﬀerent doses
of the drug, combinations of the drug with siRNA perturba-
tions, combinations with other drugs, and measurements at
diﬀerent time points.
2.2. Case study
In a collaborative eﬀort, Novartis and GNS scientists uti-
lized the BN-based inference framework to characterize the
molecular pathways aﬀected by a compound of current clinical
interest in two diﬀerent preclinical (animal) models. The multi-
omic data consisted of gene expression proﬁles from tissueFig. 2. Inference model of tissue toxicity. The inference engine generates the o
well as connections of expressed genes to additional molecular and physiol
compound and its active analogue and its connections to key genes. The funct
interpretation of the results. Other data, such as PCR measurements on partic
reveal novel markers for drug toxicity such as GeneID 217430, a new unchara
analogue (green node).microarray measurements obtained from in vivo studies for
various experimental treatment groups, including a high-
compound dose, low-compound dose, high dose of the
compounds irreversibly active analogue, high dose of the com-
pounds irreversibly inactivated analogue, and control. Time
series of gene expression data from a separate animal study
were also used. Also, a total of three adjacent tissues within
one organ were isolated and analyzed separately via inference
modeling. Concomitant non-genomic molecular and physio-
logical measurements were obtained: immunohistochemistry
staining and RT-PCR data, tissue pathology scores, animal
physiology and blood biochemistry readouts.
At the level of gene expression, some genes followed a clear
dose–response relationship, whereas other genes followed
more ambiguous patterns of expression. The modeling engine
inferred, solely based on the various datasets, connections of
expressed genes to additional molecular and physiological
measurements (Fig. 2). Eﬀects of the various compound treat-
ment conditions were delineated by including in the model
gene–gene network nodes that represent the high-dose com-
pound and its active analogue. This allowed scientists to exam-
ine classes of biological pathways that were aﬀected by the
drug in speciﬁc tissues, as well as to discern how such path-
way-based eﬀects were inﬂuenced by low vs. high dose, or by
the compound vs. fully active or inactive analogues. Further-verall connections of the network of genes from the microarray data as
ogical measurements. The box shows a closeup view of the high-dose
ional role of those genes was overlaid on the network model to facilitate
ular genes were incorporated into the inference model. The models also
cterized genes, that connects to the high-dose compound and its active
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lowed researchers to determine whether compound-activated
pathway-based mechanisms in one tissue were similar to, con-
nected to, or independent from those in an adjacent tissue.
In general, the inferred connections among molecular enti-
ties conﬁrmed known fragments of actual biological path-
ways and pathway inter-connectivity, as modulated by
compound treatment in the tissues of interest. This inferred
ensemble of models was generally consistent with indepen-
dent ﬁndings using standard statistical methods for ﬁltering
and clustering, expert knowledge, and semi-automated map-
ping tools. Moreover, the model formed a basis for addi-
tional hypothesis testing via the study of speciﬁc recovered
biological relationships, whereby expressed genes of un-
known functions were linked to entities of known functions
or known biological pathways.
Coarse biological reconstructions within a BN-based infer-
ence framework may be exploited, for example to prioritize a
set of speciﬁc molecular players for further experimental con-
ﬁrmation in the context of biomarker identiﬁcation and qual-
iﬁcation, given a disease and a tissue of interest. However,
when using sparse datasets BN-based inference results may
be confounded by a signiﬁcant number of false positive (also
false negative) connections. Such drawbacks may be mini-
mized by using additional provably robust learning techniques,
by including in an iterative fashion adequate prior biological
knowledge, and by maximizing the use of time series (kinetic)
information.Fig. 3. Mechanistic simulation of the mammalian cell cycle. This mechan
VisualCellTM software platform (custom software platform developed at
diagrammatic cell language [42]. Simulation time course proﬁles of modiﬁed
are shown as well.3. Mechanistic simulations for drug development
A mechanistic modeling approach allows the dynamical
behavior of the system to be studied in a manner that could
lead to discovering optimal ways to manipulate system compo-
nents by drugs (Fig. 3). A number of models have appeared in
the literature for signaling pathways [26–34], which have
yielded some insight into the mechanisms underlying com-
pounds that target these pathways. For example, a model of
PLC-c pathway [31] illustrated that the inhibition of the en-
zyme using aminosteroid U73122 will require very high-drug
concentrations and thus will be ineﬃcient; a better choice
would be inhibiting the supply of its substrate PIP2 instead.
Since persistent NF-jB activation is associated with tumor for-
mation, growth, and metastasis [34], the model evaluated
diﬀerent therapeutic strategies by inhibiting diﬀerent compo-
nents in the NF-jB pathway. The model was able to illustrate
that competitive inhibition of IKK, and of IjB-alpha degrada-
tion by the approved drug proteasome inhibitor bortezomib,
resulted in strong oscillatory behavior of NF-jB at realistic
doses. In contrast, direct inhibition of NF-jB by a hypotheti-
cal inhibitor will result in consistent reductions in nuclear NF-
jB concentrations.
As most drugs aﬀect multiple pathways and biological
processes, pharmaceutical applications of computational ap-
proaches will often require mechanistic models that encompass
larger scales than typically found in the literature. GNS has
developed a comprehensive model of human colon canceristic simulation of mammalian cell cycle control was encoded in the
GNS). Biological entities in the model are represented using the
states of APCC, total Emi, active CDK1 complexes, and total CyclinB
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metabolic, and genetic regulatory networks [35]. This model
was used to simulate the eﬀect of siRNA knockdown experi-
ments; the model predictions were signiﬁcantly better than ran-
dom guesses, and also better than literature-based rankings [4].
Models created from molecular interactions up to the tissue le-
vel can be classiﬁed as ‘‘bottom-up’’ because system-level
behavior is explained in terms of speciﬁc molecular mecha-
nisms. Alternately, models that consider quantitative relation-
ships between system components at a macro-level, without
necessarily encoding all the speciﬁc pathways at the cellular le-
vel, can be classiﬁed as ‘‘top-down’’. For example, Entelos has
developed a computational airway model that encompassed
certain inﬂammatory eﬀector systems [36]. Using their model
they are able to successfully reproduce the eﬀect of therapeu-
tics (leukotriene receptor antagonist and long-acting b2-ago-
nist) on clinically observed eﬃcacy endpoints in exercise-
induced asthma.
High predictive power of mechanistic models comes at a cost
of both (i) requiring knowledge of the complete set of molecu-
lar interactions in a network and (ii) knowing sets of parameter
values associated with model equations. If reasonable motiva-
tion exists for several alternative sets of postulated molecular
interactions, mechanistic modeling can be used to suggest
and test hypotheses to help distinguish between these parame-
ter sets. Parameter values are often found by optimizing model
output against experimentally observed quantities. This consti-
tutes a challenging problem for models of realistic size, because
typically the number of parameters is larger than the number
of feasible ways to perturb the system experimentally. Also,
adequate experimental methods to generate the dynamical
data on mRNA and protein concentrations of necessary qual-
ity and in a high-throughput manner are still largely lacking.
Examining the model for high sensitivity to parameter varia-
tion helps ﬁnd quantities whose measurements can best con-
strain the model. In addition, some progress has been made
in solving parameter optimization problems of large dimen-
sions, especially in context of biochemical kinetics. For exam-
ple, [37] examined parameter optimization in a multi-step
biochemical pathway and found that amongst several global
deterministic and stochastic optimization methods, an evolu-
tionary strategy (a hybrid method between random search
and genetic algorithms) gave the most accurate results, albeit
at higher computational cost.4. Combined framework for computationally driven drug
development
Inference models generally give a global view of biological
drug eﬀects, but do not reveal detailed biological mechanisms
(particularly those based on BN algorithms). Mechanistic sim-
ulations, while limited in scope, provide insights into the
dynamical response of the system. Inference modeling is the
ﬁrst step in using a computationally driven framework to pro-
cess multi-omic proﬁling data (Fig. 1). This yields regulatory
models 1 underlying the pathophysiology of the drug that
determine biological relationships between molecular as well
as phenotypic and physiological endpoints. The inference
models suggest molecular networks aﬀected by the drug that
determine the scope of the mechanistic simulations. Further
details on biological mechanisms for building the simulationsare obtained from relevant experiments reported in the litera-
ture. Dynamical time-course measurements can be used to
constrain the models via optimization algorithms followed
by robustness analysis to assess model accuracy [38]. In addi-
tion, hypotheses on new interactions suggested by the inference
models can be tested within the mechanistic models to deter-
mine if such interactions improve their accuracy. Predictions
generated from these complementary approaches can be fol-
lowed by various iterations of modeling and targeted experi-
ments to improve accuracy of model predictions.
In the future it will be more powerful to interlink the two
types of modeling methods in an automated framework. A
BN inference algorithm can be used to generate probable inter-
actions and convert them into mechanistic ‘‘modules’’. A
‘‘module’’ in this context has a small size relative to the dimen-
sions of the multi-omic data set and can be composed of one or
more interacting model components. A global optimization
algorithm can iterate over all possible combinations of the
modules (mechanistic models) while minimizing a cost func-
tion that embodies the diﬀerence between the experimental
data and predictions of the generated models until the desired
accuracy is achieved. The development of such an automated
framework will be challenging, especially towards applications
of large-scale biological models which will require both
algorithmic advances (e.g., in global optimization) and compu-
tational power. Another limitation will be acquiring the
large-scale quantitative proteomic measurements required to
constrain mechanistic models that integrate protein signal
transduction with gene expression and metabolic networks
(see [39–41] for recent promising quantitative large-scale pro-
teomics methods).
This combined approach can be utilized in all stages of drug
development to impact decision making by providing insights
into the biological factors contributing to drug eﬃcacy and
safety even with current methods and limitations. The compu-
tational biology approach described here allows for the devel-
opment of a framework where all of the knowledge on a
disease and corresponding drug response is encapsulated in
models that continue to evolve and improve in accuracy as
more data and knowledge are incorporated into the system.
These models provide an integrative, predictive tool for drug
development.
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